Live sessions agenda - ERS Respiratory Channel

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2019 - Targeting the detrimental effects of sleep disturbances and disorders ? towards personalized treatment in respiratory diseases

What are the main mechanisms of oncogenic addiction?

Joanna Chorostowska (Poland)

Replay

Accompanying documents

Are KRAS mutations druggable?

Marina Garassino (Italy)

Replay

Slides

Accompanying documents

How does the cancer immunity circle operate (or dysoperate)?

Daan Hurkmans (Netherlands), Joachim Aerts (Netherlands)

Assembly Symposium

Replay

Slides

Accompanying documents

Session 1: From molecular alterations to cancer immunity in NSCLC - Panel discussion

Joanna Chorostowska (Poland), Marina Garassino (Italy), Daan Hurkmans (Netherlands)

Assembly Symposium

Replay

Molecular diagnosis for oncogenic addictions

Patrick Pauwels (Belgium)

Replay

Slides

Accompanying documents

When and how to identify resistance mechanisms to targeted therapies

Nicolas Girard (France)

Replay

Slides

Predictive biomarker of immune checkpoint inhibitors efficacy

Thierry Berghmans (Belgium), Luis Paz-Ares (Spain)

Assembly Symposium

Replay

Slides

Session 2: From molecular target to molecular resistance in NSCLC - Panel discussion

Patrick Pauwels (Belgium), Nicolas Girard (France), Luis Paz-Ares (Spain)

Replay

Therapeutic strategy for EGFR driven NSCLC

Jacques Cadranel (France)

Replay

Slides

Accompanying documents

Therapeutic strategy for ALK/ROS driven NSCLC

Jan Van Meerbeeck (Belgium)

Replay

Slides

Therapeutic strategy for other oncogenic drivers

David Planchard (France)

Replay

Slides

Session 3: From molecular addiction to therapeutic strategy in NSCLC - Panel discussion

Jacques Cadranel (France), Jan Van Meerbeeck (Belgium), David Planchard (France)

Replay

From anti-PD1/L1 inhibitors to new immunotherapies

Thierry Berghmans (Belgium)

Replay

Slides

Accompanying documents

Which immunotherapy for which patients?

Lizza Hendriks (Netherlands)

Replay

Slides

Accompanying documents

Combination therapy in the era of immunotherapy

Anne-Marie Dingemans (Netherlands)

Replay

Slides

Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC - Panel discussion

Thierry Berghmans (Belgium), Lizza Hendriks (Netherlands), Anne-Marie Dingemans (Netherlands)

Replay

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

#{title}